Ocugen (OCGN) Competitors $0.93 +0.02 (+2.09%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. CVAC, PHVS, CRMD, NAGE, BCAX, ELVN, ZYME, LENZ, CMRX, and CDMOShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include CureVac (CVAC), Pharvaris (PHVS), CorMedix (CRMD), Niagen Bioscience (NAGE), Bicara Therapeutics (BCAX), Enliven Therapeutics (ELVN), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Ocugen vs. CureVac Pharvaris CorMedix Niagen Bioscience Bicara Therapeutics Enliven Therapeutics Zymeworks LENZ Therapeutics Chimerix Avid Bioservices CureVac (NASDAQ:CVAC) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment. Is CVAC or OCGN more profitable? CureVac has a net margin of 20.72% compared to Ocugen's net margin of -532.51%. CureVac's return on equity of 21.98% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets CureVac20.72% 21.98% 15.72% Ocugen -532.51%-154.75%-90.79% Do insiders and institutionals have more ownership in CVAC or OCGN? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, CVAC or OCGN? Ocugen has lower revenue, but higher earnings than CureVac. Ocugen is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$535.18M1.74-$281.58M$0.825.07Ocugen$4.52M59.02-$63.08M-$0.19-4.81 Does the MarketBeat Community prefer CVAC or OCGN? Ocugen received 88 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 71.43% of users gave Ocugen an outperform vote while only 56.25% of users gave CureVac an outperform vote. CompanyUnderperformOutperformCureVacOutperform Votes2756.25% Underperform Votes2143.75% OcugenOutperform Votes11571.43% Underperform Votes4628.57% Which has more volatility and risk, CVAC or OCGN? CureVac has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.21, indicating that its stock price is 321% more volatile than the S&P 500. Does the media favor CVAC or OCGN? In the previous week, CureVac had 1 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for CureVac and 3 mentions for Ocugen. Ocugen's average media sentiment score of 1.26 beat CureVac's score of 0.10 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CVAC or OCGN? CureVac currently has a consensus price target of $14.00, indicating a potential upside of 236.54%. Ocugen has a consensus price target of $6.00, indicating a potential upside of 556.53%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOcugen beats CureVac on 9 of the 17 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$266.89M$2.93B$5.33B$8.39BDividend YieldN/A1.64%5.21%4.11%P/E Ratio-5.0831.1826.7119.71Price / Sales59.02398.78386.47120.65Price / CashN/A168.6838.2534.62Price / Book5.713.236.774.50Net Income-$63.08M-$72.35M$3.23B$248.22M7 Day Performance20.50%2.49%0.48%-0.78%1 Month Performance26.75%2.45%9.10%11.53%1 Year Performance-48.66%-24.98%18.56%8.99% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.1897 of 5 stars$0.93+2.1%$6.00+543.1%-46.9%$272.47M$4.52M-5.1880Positive NewsCVACCureVac3.57 of 5 stars$3.84+3.2%$14.00+264.6%+6.4%$861.46M$535.18M6.98880News CoverageEarnings ReportAnalyst RevisionGap DownPHVSPharvaris1.2631 of 5 stars$16.44-0.7%$40.67+147.4%-17.9%$859.65MN/A-5.8730CRMDCorMedix2.0894 of 5 stars$12.65+3.0%$15.00+18.6%+135.3%$857.99M$82.55M-15.6230Positive NewsNAGENiagen BioscienceN/A$10.88-0.6%N/AN/A$857.02M$107.93M64.00120News CoverageGap DownBCAXBicara Therapeutics1.6377 of 5 stars$15.40+6.4%$32.00+107.8%N/A$839.85MN/A0.0032News CoverageAnalyst DowngradeGap DownELVNEnliven Therapeutics2.4752 of 5 stars$16.84-0.1%$37.25+121.2%-26.7%$826.32MN/A-8.8650Gap UpZYMEZymeworks3.3572 of 5 stars$11.79+0.7%$21.00+78.1%+27.3%$820.31M$93.38M-7.86460News CoveragePositive NewsAnalyst ForecastAnalyst RevisionLENZLENZ Therapeutics1.9254 of 5 stars$28.57+6.6%$46.60+63.1%+53.3%$804.13MN/A-16.14110CMRXChimerix0.5651 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990CDMOAvid Bioservices0.806 of 5 stars$12.50+0.1%$12.25-2.0%+37.5%$799.18M$139.91M-5.23320High Trading Volume Related Companies and Tools Related Companies CureVac Alternatives Pharvaris Alternatives CorMedix Alternatives Niagen Bioscience Alternatives Bicara Therapeutics Alternatives Enliven Therapeutics Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives Chimerix Alternatives Avid Bioservices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.